These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family. Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662 [TBL] [Abstract][Full Text] [Related]
5. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989 [TBL] [Abstract][Full Text] [Related]
6. Malignant hyperthermia. Ali SZ; Taguchi A; Rosenberg H Best Pract Res Clin Anaesthesiol; 2003 Dec; 17(4):519-33. PubMed ID: 14661655 [TBL] [Abstract][Full Text] [Related]
7. Malignant Hyperthermia Susceptibility and Fitness for Duty. Lee MA; McGlinch EB; McGlinch MC; Capacchione JF Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972 [TBL] [Abstract][Full Text] [Related]
8. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests]. Mortier W; Breucking E Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201 [TBL] [Abstract][Full Text] [Related]
9. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility. Allen GC; Rosenberg H; Fletcher JE Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777 [TBL] [Abstract][Full Text] [Related]
10. Malignant hyperthermia: clinical and molecular aspects. Correia AC; Silva PC; da Silva BA Rev Bras Anestesiol; 2012; 62(6):820-37. PubMed ID: 23176990 [TBL] [Abstract][Full Text] [Related]
11. Anesthetic experience for patients with malignant hyperthermia susceptibility determined by molecular genetic test: A report of 2 cases. Lee JW; Yi JS; Lee JR; Kim DC Korean J Anesthesiol; 2009 Sep; 57(3):387-391. PubMed ID: 30625893 [TBL] [Abstract][Full Text] [Related]
15. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility. Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of suspected malignant hyperthermia events during anesthesia. Schuster F; Johannsen S; Schneiderbanger D; Roewer N BMC Anesthesiol; 2013 Sep; 13(1):24. PubMed ID: 24053352 [TBL] [Abstract][Full Text] [Related]
17. Malignant hyperthermia. Ben Abraham R; Adnet P; Glauber V; Perel A Postgrad Med J; 1998 Jan; 74(867):11-7. PubMed ID: 9538480 [TBL] [Abstract][Full Text] [Related]
18. The current status of malignant hyperthermia. Yang L; Tautz T; Zhang S; Fomina A; Liu H J Biomed Res; 2019 May; 34(2):75-85. PubMed ID: 32305961 [TBL] [Abstract][Full Text] [Related]